MedTronic study says cardiac resynchronization therapy cost effective

By Elaine Rigoli

Tampa, Fla., Sept. 5 - MedTronic, Inc. said long-term treatment with cardiac resynchronization therapy with an implantable cardioverter defibrillator is a cost-effective way to improve survival in patients with heart failure.

The company said study results suggest that, for patients with moderate or severe heart failure, cardiac resynchronization therapy is a treatment that improves symptoms and reduces mortality, a finding that is further supported by a meta-analysis of reported studies.

The cost-effectiveness of cardiac resynchronization therapy is based on the proven clinical evidence of improvements in quality of life, morbidity, mortality and reduction in costs associated with hospitalization for heart failure, the Minneapolis-based medical-technology company added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.